Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates.

Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.

[1]  Ronald N. Jones,et al.  Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) , 2019, Antimicrobial Agents and Chemotherapy.

[2]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous colistin in pediatric patients: Implications for selection of dosage regimens. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Paterson,et al.  Dosing Guidance for Intravenous Colistin in Critically Ill Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Imberti,et al.  Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates , 2016, The Pediatric Infectious Disease Journal.

[5]  H. Goossens,et al.  The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. , 2016, The Journal of antimicrobial chemotherapy.

[6]  Brian T. Tsuji,et al.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.

[7]  Bryan T Grenfell,et al.  Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. , 2014, The Lancet. Infectious diseases.

[8]  J. Turnidge,et al.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.

[9]  W. Couet,et al.  Colistin pharmacokinetics: the fog is lifting. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.